Covid-CKD

Photo by UBC Brand & Marketing on Flickr

Project Overview

The purpose of the “Determining the Safety and Efficacy of COVID-19 Vaccination in the Chronic Kidney Disease Population” (COVID-CKD) project was to to characterize the longitudinal serologic response to COVID-19 vaccination among individuals with CKD stages 3b, 4 and 5; (i.e., a GFR < 45 ml/min) in British Columbia and Ontario.

Participants were recruited prior to or following any COVID-19 vaccine dose and had blood sampled for serological testing at multiple timepoints: 1, 3, 6, 9, and 12 months post vaccination. The data from this large multicenter study will inform on the strength and duration of the immune response to COVID-19 vaccination in individuals with kidney disease, and identify key factors associated with variability in that response.

The British Columbia component of the COVID-CKD project was led by Adeera Levin, Professor of Medicine, Head Division of Nephrology at the University of British Columbia, and Consultant nephrologist at Providence Health Care/ St Paul’s Hospital, in Vancouver Canada.

“As this study started in 2021, the FoMDS Data Management team really helped us with utilizing the e-consent feature of Redcap and were prompt in responding with any issues or questions that arose. In addition, with rapid changes that were happening in vaccine policy during the study, we often had to add or adjust data fields within our project and the team was very quick and helpful in reviewing and administering those changes. The team also assisted us in utilizing some of the great features in Redcap, such as the calendar, data quality rules, and longitudinal data mode.”

–Dr. Adeera Levin